Business
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and develope
About this update from Gan & Lee Pharmaceuticals Co., Ltd. Class A
[{"type":"text","content":"BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and developed by Gan & Lee.","length":598,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/0d0a07ba07bb978e5850cb78704c85c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5HoulffK6Wt_my107c_.Wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MQ--/https://media.zenfs.com/en/prnewswire.com/0d0a07ba07bb978e5850cb78704c85c9","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2952241/image1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Strategic Alliance: By Leveraging JW's Strengths in R&D and Commercialization in South Korea, Gan & Lee Will Establish a Strong Commercial Footprint in South Korea's High-Potential Metabolic Disease Market ","length":221,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, JW Pharmaceutical will be granted the exclusive rights to develop and commercialize Bofanglutide Injection in South Korea. Gan & Lee Pharmaceuticals will receive a one-time, non-refundable upfront payment of USD 5 million. Additionally, Gan & Lee is eligible to receive milestone payments totaling USD 76.1 million, contingent upon research and development progress, regulatory approvals, and commercialization achievements. Following the product's commercial launch, Gan & Lee will also receive tiered royalties based on net sales. The total potential transaction value reaches up to USD 81.1 million (excluding royalties).","length":674,"tagName":"p"},{"type":"text","content":"This collaboration marks the third overseas out-licensing deal for Gan & Lee's Bofanglutide Injection, following previous partnersh...
More updates from Gan & Lee Pharmaceuticals Co., Ltd. Class A